Literature DB >> 10837476

An analysis of the interaction between mouse apolipoprotein B100 and apolipoprotein(a).

E J Cheesman1, R J Sharp, C H Zlot, C Y Liu, S Taylor, S M Marcovina, S G Young, S P McCormick.   

Abstract

The assembly of lipoprotein(a) (Lp(a)) involves an initial noncovalent interaction between apolipoprotein (apo) B100 and apo(a), followed by the formation of a disulfide bond between apoB100 cysteine 4326 and apo(a) cysteine 4057. The structural features of apoB100 that are required for its noncovalent interaction with apo(a) have not been fully defined. To analyze that initial interaction, we tested whether apo(a) could bind noncovalently to two apoB proteins that lack cysteine 4326: mouse apoB100 and human apoB100-C4326G. Our experiments demonstrated that both mouse apoB and the human apoB100-C4326G bind noncovalently to apo(a). We next sought to gain insights into the apoB amino acid sequences required for the interaction between apoB100 and apo(a). Previous studies of truncated human apoB proteins indicated that the carboxyl terminus of human apoB100 (amino acids 4330-4397) is important for Lp(a) assembly. To determine whether the carboxyl terminus of mouse apoB100 can interact with apo(a), transgenic mice were produced with a mutant human apoB gene construct in which human apoB100 amino acids 4279-4536 were replaced with the corresponding mouse apoB100 sequences and tyrosine 4326 was changed to a cysteine. The mutant apoB100 bound to apo(a) and formed bona fide disulfide-linked Lp(a), but Lp(a) assembly was less efficient than with wild-type human apoB100. The fact that Lp(a) assembly was less efficient with the mouse apoB sequences provides additional support for the notion that sequences in the carboxyl terminus of apoB100 are important for Lp(a) assembly.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10837476     DOI: 10.1074/jbc.M002772200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Generation and characterization of LPA-KIV9, a murine monoclonal antibody binding a single site on apolipoprotein (a).

Authors:  Ayelet Gonen; Xiaohong Yang; Calvin Yeang; Elena Alekseeva; Marlys Koschinsky; Joseph L Witztum; Michael Boffa; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2020-07-08       Impact factor: 5.922

2.  Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice.

Authors:  Indumathi Chennamsetty; Karam M Kostner; Thierry Claudel; Manjula Vinod; Sasa Frank; Thomas S Weiss; Michael Trauner; Gerhard M Kostner
Journal:  J Lipid Res       Date:  2012-08-28       Impact factor: 5.922

3.  Lipoprotein(a) accelerates atherosclerosis in uremic mice.

Authors:  Tanja X Pedersen; Sally P McCormick; Sotirios Tsimikas; Susanne Bro; Lars B Nielsen
Journal:  J Lipid Res       Date:  2010-06-28       Impact factor: 5.922

4.  Lipoprotein(a): biology and clinical importance.

Authors:  Sally P A McCormick
Journal:  Clin Biochem Rev       Date:  2004-02

5.  Statins and Lp(a): The plot thickens.

Authors:  Byambaa Enkhmaa; Lars Berglund
Journal:  Atherosclerosis       Date:  2019-08-06       Impact factor: 5.162

6.  Human apoB contributes to increased serum total apo(a) level in LPA transgenic mice.

Authors:  Päivi A Teivainen; Knut A Eliassen; Edward M Rubin; Srdjan Djurovic; Kåre Berg
Journal:  Lipids Health Dis       Date:  2004-05-11       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.